DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
7th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)
Piper Sandler 36th Annual Healthcare Conference
Date/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
| Last Trade: | US$30.00 |
| Daily Change: | -0.70 -2.28 |
| Daily Volume: | 1,167,574 |
| Market Cap: | US$4.950B |
October 28, 2025 October 22, 2025 September 08, 2025 July 29, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
